BioMarin to Pay Up to $840 Million for Prosensa

BioMarin Pharmaceutical said it agreed to acquire Prosensa Holding NV, a bet that regulators will approve Prosensa’s lead product candidate for a rare form of muscular dystrophy.



from WSJ.com: US Business http://ift.tt/1peHOlO

via IFTTT